ArticleStem cell research & therapy2026
DLP bioprinting of cartilage organoid-laden bioinks yields high-fidelity auricular constructs with enhanced chondrogenesis.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo develop and validate a cartilage organoid (CO)-laden digital light processing (DLP) bioprinting strategy for auricular reconstruction and to compare its performance with conventional chondrocyte-laden prints. MATERIALS AND
methodsRat bone-marrow stromal cells (BMSCs) were aggregated into spheroid and chondrogenically induced to form CO. Organoid construction and characterization included EdU proliferation assay, CD73/CD90 immunofluorescence (IF), and real-time quantitative polymerase chain reaction (qPCR) of chondrogenic genes. O-nitrobenzyl functionalized gelatin (GelNB)/ methacrylated hyaluronic acid (HAMA) bioinks were screened by gross morphology, tensile/ compressive mechanics, enzymatic degradability (0.1% collagenase II), and swelling, identifying 10% (w/v) GelNB + 1% (w/v) HAMA as the working bioink. Full-scale ears were DLP-printed from acellular, chondrocyte-laden, or CO-laden inks. In vitro, whole-mount Live/Dead imaging was performed at 7/14/21 days and qPCR quantified COL2A1, aggrecan (ACAN), COL10A1. In vivo, constructs were implanted subcutaneously in nude mice and analyzed at 4/8 weeks by Hematoxylin-eosin (H&E), Safranin O/Fast Green, ACAN and COL II IHC staining, and compressive Young's modulus measurement on implants.
resultsThe 10% GelNB + 1% HAMA ink balanced print fidelity, mechanical robustness, and controlled degradability. Loading CO did not impair printability. During 21-day culture, viability remained high; at day 21, CO-laden ears showed higher COL2A1/ACAN and lower COL10A1 than chondrocyte-laden controls. After implantation, CO-laden explants exhibited more abundant lacuna-like cartilage morphology, stronger ACAN and COL II staining, increased EVG-positive elastic fiber-associated matrix, and a higher compressive Young's modulus at 8 weeks.
conclusionsCO-laden DLP bioprinting enhances chondrogenesis and mitigates hypertrophy versus chondrocyte-laden printing, offering an exploratory high-fidelity strategy for auricular cartilage-like tissue engineering rather than definitive mature elastic cartilage regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.